Atlas Trials

Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Clinical trial NCT03451331 · COMPLETED

Trial details

NCT number
NCT03451331
Sponsor
Matthew Galsky
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Urothelial Cancer
Start date
2018-05-10
Primary completion
2023-06-07
Enrollment
49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.